drugset / Trial / NCT00321672

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00321672

Phase 3 Completed 494 enrolled NeurogesX
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study was to assess the efficacy and safety of NGX-4010 applied for 30 or 60 minutes for the treatment of painful HIV-associated neuropathy.

Timeline

Start
2006-06
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 0.04 % Topical
Subject Capsaicin Small molecule 8 % Topical